CytomX Therapeutics (CTMX) Change in Account Payables (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Change in Account Payables came in at $67000.0 in Q1 2026, up 108.33% YoY from $32160.0 in Q1 2025, and down 89.77% on a QoQ basis from $655000.0 in Q4 2025.
CytomX Therapeutics (CTMX) Change in Account Payables (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Change in Account Payables data on file, last reported at $67000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 108.33% year-over-year to $67000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 164.92% YoY) and the FY2025 annual result came in at $221000.0, up 174.41% from the prior year.
- Change in Account Payables declined to $67000.0 in Q1 2026, from $655000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $3.3 million in Q3 2022 to a low of -$2.4 million in Q4 2022.
- A 5-year average of -$80411.8 and a median of -$49000.0 in 2025 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2022 — Change in Account Payables surged 1875.68% — and 2023, when it plunged 635.19%.
- Tracing CTMX's Change in Account Payables over 5 years: stood at -$2.4 million in 2022, then soared by 86.18% to -$328000.0 in 2023, then climbed by 20.43% to -$261000.0 in 2024, then surged by 350.96% to $655000.0 in 2025, then sank by 89.77% to $67000.0 in 2026.
- The last three Change in Account Payables figures came in at $67000.0 (Q1 2026), $655000.0 (Q4 2025), and $419000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 571,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 571,000.00 |
| Jun 30, 2026 | 571,000.00 |
| Mar 31, 2026 | 67,000.00 |
| Mar 31, 2026 | 67,000.00 |
| Dec 31, 2025 | 655,000.00 |
| Dec 31, 2025 | 655,000.00 |
| Sep 30, 2025 | 419,000.00 |
| Sep 30, 2025 | 419,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | -804,000.00 |
| Mar 31, 2025 | -804,000.00 |
| Dec 31, 2024 | -261,000.00 |
| Dec 31, 2024 | -261,000.00 |
| Sep 30, 2024 | 811,000.00 |
| Sep 30, 2024 | 811,000.00 |
| Jun 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -1.43 Mn |
| Mar 31, 2024 | 581,000.00 |
| Mar 31, 2024 | 581,000.00 |